
Nippon India Pharma Fund (G)
Equity · Sectoral
11.76%
Last 1 year
- Exit Load
- 1.00%
- Expense Ratio
- 1.83%
- Min. AmountMin. SIP Amount
- ₹100
- Min. Lump SumMin. Lump sum
- ₹5,000
Historical View
Return Calculator
- Invested Amount
- ₹9,00,000
- Calculated AmountCurrent Value
- ₹11,70,990
- IRR
- 16.532%
- Absolute Gain
- +₹2,70,990 (+30.1%)
Returns & Rankings
Category: Equity Sectoral


63 ProductsEquity Sectoral Funds


63 ProductsWealthy Score
Return Score rates how well the fund has rewarded investors over time, comparing its returns across periods with other funds in its category.
- 1Y Returns
- 11.8%
- 3Y Returns
- 16.5%
- 5Y Returns
- 13.8%
- Alpha
- 11.47
Holding Analysis
Equity/Debt/Cash Split
- Equity99.6%
- Debt0.4%
Market Cap Weightage
- Mid Cap49%
- Large Cap29.5%
- Small Cap21.1%
- Others0.4%
Sector allocation
- Healthcare97.4%
- Consumer Discretionary2.3%
- Debt0.4%
Top 10 HoldingsTop Holdings
| Stocks | Sector | Percentage |
|---|---|---|
| Sun Pharma.Inds. | Pharmaceuticals | 11.55% |
| Divi's Lab. | Pharmaceuticals | 6.73% |
| Cipla | Pharmaceuticals | 6.21% |
| Lupin | Pharmaceuticals | 6.16% |
| Dr Reddy's Labs | Pharmaceuticals | 6.13% |
| Apollo Hospitals | Healthcare | 5.1% |
| Mankind Pharma | Pharmaceuticals | 4.4% |
| Sai Life | Pharmaceuticals | 4.04% |
| Ajanta Pharma | Pharmaceuticals | 3.53% |
| Max Healthcare | Healthcare | 3.31% |
- 11.55%
Sun Pharma.Inds.
Pharmaceuticals
- 6.73%
Divi's Lab.
Pharmaceuticals
- 6.21%
Cipla
Pharmaceuticals
- 6.16%
Lupin
Pharmaceuticals
- 6.13%
Dr Reddy's Labs
Pharmaceuticals
Top Funds in the Category
| Fund Name | Rating | Category | 1Y | 3Y |
|---|---|---|---|---|
| — | Equity | 16.23% | 29.6% | |
| — | Equity | 28.41% | 28.89% | |
| — | Equity | 23.71% | 23.26% | |
| — | Equity | 20.06% | 21.85% | |
| — | Equity | 24.28% | 21.75% |
Peer Comparison
Nippon India Pharma Fund (G)
- 1 Y Return
- 11.76%
- 3 Y Return
- 16.53%
- 5 Y Return
- 13.75%
Nifty 50
- 1 Y Return
- -2.32%
- 3 Y Return
- 9.41%
- 5 Y Return
- 8.00%
Investment Objective
The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies
Fund Management

Sailesh Raj Bhan
Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.
Riskometer
- Risk Score
- 6
- Risk Level
- Very High
Advanced Ratios
- AlphaReturn earned over the benchmark after adjusting for risk. Higher is better.
- 11.47
- BetaHow much the fund moves with the market. Above 1 means more volatile than the market.
- 0.65
- SRSharpe Ratio: return earned per unit of total risk taken. Higher is better.
- 0.78
- SDStandard Deviation: how much returns swing around their average. Lower means steadier returns.
- 14.85
- TRTreynor Ratio: return earned per unit of market risk (beta). Higher is better.
- 0.03
- P/EPrice to Earnings of the stocks the fund holds. Higher means a pricier portfolio.
- 43.73
Tax Implication
STCG Tax: 20% if redeemed before 1 Year. LTCG Tax: 12.5% exceeding Rs. 1,25,000/- post 1 Year
FAQs
Nippon India Pharma Fund – Regular Plan - Growth was launched 22 years ago and has delivered annualised returns (CAGR) of 19.83% since inception. Here is how it compares with the category average:
Period Fund Category average 1 Year 11.76% 6.93% 3 Years 16.53% 14.57% 5 Years 13.75% 11.55% Since Inception 19.83% Returns as on 18 Nov 2026. 1-year returns are absolute; returns above 1 year are CAGR. Past performance may or may not be sustained in future.
The expense ratio of Nippon India Pharma Fund – Regular Plan - Growth is 1.83%. This is the annual fee for managing and operating the fund. It is adjusted in the daily NAV, so the returns you see are already net of this cost.
Nippon India Pharma Fund is rated Very High risk on the SEBI riskometer. The riskometer has six levels, from Low to Very High, and fund houses review it every month.
You can start an SIP in Nippon India Pharma Fund with ₹100 a month, or invest a lump sum of ₹5,000. Additional investments start at ₹1,000.
Nippon India Pharma Fund charges an exit load of 1% if redeemed within 1 month of investment. The exit load is deducted from the redemption amount.
No, Nippon India Pharma Fund has no lock-in period, so you can redeem anytime. An exit load may apply on early redemption.
Nippon India Pharma Fund manages assets (AUM) of approximately ₹9,087 Cr.
As on 31 Oct 2026, Nippon India Pharma Fund holds 40 securities. These are its top 10 holdings:
Company % of portfolio Sun Pharma.Inds. 11.55% Divi's Lab. 6.73% Cipla 6.21% Lupin 6.16% Dr Reddy's Labs 6.13% Apollo Hospitals 5.10% Mankind Pharma 4.40% Sai Life 4.04% Ajanta Pharma 3.53% Max Healthcare 3.31% As on 31 Oct 2026, these are the fund's largest sector allocations:
Sector % of portfolio Healthcare 97.36% Consumer Discretionary 2.26% Debt 0.38% If you invested through a Wealthy partner, you can place a redemption request in the Wealthy app, or ask your partner to do it for you. If you invested elsewhere, you can redeem through the Nippon Mutual Fund website, MF Central or KARVY. The money is credited to your registered bank account, usually within a few working days. Exit load and capital gains tax may apply.












